NeoImmuneTech, Inc. Logo

NeoImmuneTech, Inc.

Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.

950220 | KO

Overview

Corporate Details

ISIN(s):
KR8840140006
LEI:
Country:
United States of America
Address:
2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biotechnology company dedicated to developing novel immuno-therapeutics. Founded in 2014, the company's core technology is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 designed to amplify the quantity and enhance the functionality of T cells. This proprietary asset is being developed to treat various cancers and infectious diseases. NeoImmuneTech's research and development efforts focus on exploring NT-I7 as both a monotherapy and in combination with other treatments, aiming to expand the horizons of immuno-oncology and address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 94.2 KB
2025-09-16 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
Korean 7.8 KB
2025-09-16 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 90.0 KB
2025-09-15 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 11.0 KB
2025-09-10 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 9.6 KB
2025-09-04 00:00
Share Issue/Capital Change
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
Korean 11.3 KB
2025-09-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.3 KB
2025-09-04 00:00
Registration Form
[발행조건확정]증권신고서(증권예탁증권)
Korean 218.3 KB
2025-09-04 00:00
Prospectus
[기재정정]투자설명서
Korean 2.7 MB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-20 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-08-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.8 KB

Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeoImmuneTech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Inventage Lab Inc. Logo
Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.
South Korea
389470
Inventiva S.A. Logo
Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.
United States of America
IVA
Invivyd, Inc. Logo
Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.
United States of America
IVVD
IO Biotech, Inc. Logo
Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.
United States of America
IOBT
IONIS PHARMACEUTICALS INC Logo
A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.
United States of America
IONS
IOVANCE BIOTHERAPEUTICS, INC. Logo
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America
IOVA
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France
IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden
IRLAB
IRONWOOD PHARMACEUTICALS INC Logo
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America
IRWD
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890

Talk to a Data Expert

Have a question? We'll get back to you promptly.